In a Dutch-Danish phase III trial reported in The New England Journal of Medicine, Rohaan et al found that tumor-infiltrating lymphocyte (TIL) therapy prolonged progression-free survival vs ipilimumab in patients with advanced melanoma.
Clinical Trials
Drug combination for stage IV melanoma shows success in CU Cancer Center trial
A new multidrug treatment for patients with stage IV melanoma has proven effective after a three-year clinical trial at the University of Colorado Cancer Center.
Microsatellites may be associated with poorer survival outcomes in melanoma
Varying therapies for the neoadjuvant and adjuvant treatment of melanoma based on staging continue to be explored with pembrolizumab (Keytruda) a common agent in both settings, according to Sapna Patel, MD.
Real-World Study Demonstrates Benefits with Adjuvant Nivolumab in Resected Stage IIIA Melanoma
A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab (Opdivo), according to a real-world analysis presented at the 19th International Congress of the Society for Melanoma Research.